Kosheeka’s Post

⚠️Cyclosporine + Tacrolimus⚠️ Key immunosuppressive drugs for transplant patients, can inhibit P-glycoprotein (P-gp), leading to higher drug levels of other P-gp substrates. P-gp is a transporter protein that plays a key role in drug distribution and excretion. When it's inhibited, levels of other P-gp substrates can increase, potentially leading to toxicity or adverse effects.This raises the risk of adverse effects or toxicity. Stay alert to potential drug interactions! #TransplantCare #DrugInteractions #Healthcare #clinicalpharmacist

AMIODARONE - The Anti-Arrythmic Drug linked to Hormonal Dysregulation. 1. Amiodarone is a widely used antiarrhythmic drug effective in treating both supraventricular and ventricular tachyarrhythmias. 2. It was initially introduced in 1962 as an antianginal compound and gained approval for antiarrhythmic use in the USA in 1985. 3. Amiodarone affects myocardial depolarization and repolarization, exhibiting class I, II, III, and IV antiarrhythmic effects. 4. Despite its efficacy, amiodarone's use is limited by potential adverse effects, including thyroid dysfunction leading to hypothyroidism or hyperthyroidism. 5. Dronedarone, a newer antiarrhythmic drug, was designed to emulate amiodarone's potency while minimizing adverse effects, making it a potential replacement in certain patient groups.

𝐋𝐮𝐩𝐢𝐧 𝐠𝐞𝐭𝐬 𝐭𝐞𝐧𝐭𝐚𝐭𝐢𝐯𝐞 𝐔𝐒𝐅𝐃𝐀 𝐧𝐨𝐝 𝐟𝐨𝐫 𝐫𝐢𝐯𝐚𝐫𝐨𝐱𝐚𝐛𝐚𝐧 𝐭𝐚𝐛𝐥𝐞𝐭𝐬 𝐮𝐬𝐞𝐝 𝐭𝐨 𝐭𝐫𝐞𝐚𝐭 𝐛𝐥𝐨𝐨𝐝 𝐜𝐥𝐨𝐭𝐬 📌Lupin received tentative approval from the United States Food and Drug Administration (USFDA) for rivaroxaban tablets on Tuesday, January 23. 📌" Lupin received tentative approval from the USFDA for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc.” 📌Rivaroxaban, which is used to prevent blood clots from forming due to an irregular heartbeat 📌The medicine is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), in addition to reducing the risk of stroke, DVT, PE and recurrent VTE in paediatric patients from birth to less than 18 years, among a few other ailments. #usfda #lupin #anda #rivaroxaban

"Drug-induced hyper/hypokalaemia" - The following two lists are for most commonly-used drugs that induce hyper or hypokalaemia. Concurrent use of two or more drugs from these list might increase the risk of hyper or hypokalaemia - Hyperkalaemia is particularly notable when ACE inhibitors or ARBs are given with k-sparing diuretics (esp. spironolactone or eplerenone) - Regarding to hypokalaemia, some drugs can cause this effect in overdose (e.g. insulin poisoning). These drugs are not included in the list - REMEMBER: hypokalaemia can increase the risk of "torsade de points", which might be additive with the effects of drugs that prolong the QT interval (I will make list for them later) References: - BNF 86, p.1494 #drug_induced_hyperkalaemia #drug_induced_hypokalaemia #clinical_pharmacology_41 #pharmacy_review #counseling_points #patient_education 

Drug Interactions: Warfarin has numerous drug interactions that can increase the risk of adverse effects or decrease warfarin's anticoagulant effect. Therefore dosing adjustments, close monitoring, and alternative agents should be considered when combining warfarin with certain medications. Caution is necessary when administering warfarin with antiplatelet agents, fibrinolytics, nonsteroidal anti-inflammatory agents (NSAIDs), antimicrobials, anti-arrhythmic drugs, and other anticoagulant agents. It is worth noting that the S-enantiomer of warfarin is approximately three to five times more potent than the R-enantiomer. Thus, drug interactions involving the inhibition of the S-enantiomer are considered more severe and may require pre-emptive dose adjustments or therapeutic interchange of alternative anticoagulants. Clinicians should reference a comprehensive drug interaction database when necessary. #Pharmacist

If you struggle with long-term pain in your legs due to #diabetes, also known as #diabeticperipheralneuropathy, the Navigator DPN 1 Study may be an #option for you. This study is researching a non-opioid investigational drug, suzetrigine, as an alternative to existing medicines for #painmanagement. To learn more, follow and DM us! #california #thousandoaks #study #sclamanagement #research #dpn #nervepain #clinicalrearch #SMO

𝗝&𝗝'𝘀 𝗔𝗰𝘁𝗲𝗹𝗶𝗼𝗻 𝗯𝘂𝘆𝗼𝘂𝘁 𝗽𝗮𝘆𝘀 𝗼𝗳𝗳 𝗮𝗴𝗮𝗶𝗻 𝘄𝗶𝘁𝗵 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗼𝗳 𝗢𝗽𝘀𝘆𝗻𝘃𝗶 𝗶𝗻 𝗽𝘂𝗹𝗺𝗼𝗻𝗮𝗿𝘆 𝗮𝗿𝘁𝗲𝗿𝗶𝗮𝗹 𝗵𝘆𝗽𝗲𝗿𝘁𝗲𝗻𝘀𝗶𝗼𝗻 Johnson & Johnson scored an FDA approval for Opsynvi, a combo of the endothelin receptor antagonist Opsumit and the phosphodiesterase 5 inhibitor tadalafil, for the treatment of pulmonary arterial hypertension. The combo is approved both for patients in the first-line setting as well as those who have already been treated with Opsumit and tadalafil as separate tablets. J&J owns Opsumit through its buyout of Actelion and tadalafil is the active ingredient of an Eli Lilly and Company drug (Cialis) that has since hit the generic market. Opsumit is a blockbuster drug that brought in $1.9 billion in 2023 and was first approved in 2013 to treat pulmonary arterial hypertension. It faces a 2025 patent cliff.  https://lnkd.in/e_YRkZr3

Eli Lilly and Company's weight loss drug tirzepatide gets approval in China A spokesperson for Eli Lily did not immediately respond to a request for comment on when its own drug's sales would begin in China or how many doses would be supplied. Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro, also approved in China, and weight-loss drug Zepbound. #keyAsianmarket I #weightlossdrug I #Wegovy I #furtherintensifyingompetition I #highestnumberofoverweight I #companiesobesitytreatments Read more: https://lnkd.in/gvMKp-mp

Here is one to watch!! ✴ Breakthrough Designation Therapy win for Ensysce Biosciences: 💊 A 'next generation opioid,' PF614-MPAR; this novel oral analgesic is formulated with overdose protection; such protection is what they believe to be a first in any drug class. "PF614-MPAR (multi-pill abuse resistance [MPAR®) is a prodrug of oxycodone that includes a trypsin inhibitor that blocks the activation and release of the opioid if too much of the product is consumed." ⚠ We are already aware of the opioid epidemic in this country. We need also to address options for safer opioid use and interventions and innovations to prevent accidental or unintentional overdoses and deaths. This technology is certain to play a role in mitigating and reducing those incidences. 📈 Shortly after this release, MarketWatch reported shares skyrocketing to 39% and eventually settled at being up by 22% that day. https://lnkd.in/eK-jCY2a #Opioids #OverdosePrevention #Overdose #SaferOpoids #AccidentalOverdose #UnintentionalOverdose #EnsysceBiosciences #Regulatory #Biosciences #Pharma #Biotech #Healthcare #Innovation

* Glenmark and Pfizer have jointly launched Abrocitinib, an oral Janus kinase (JAK) inhibitor in India, indicated for the treatment of refractory, moderate-to-severe atopic dermatitis, not adequately controlled with other systemic drug products, or when the use of these therapies is not advisable * Atopic dermatitis is one of the most common inflammatory skin diseases, characterized by erythema, itching, lichenification, induration, papulation, and oozing/crusting. Severe and continuous symptoms may disrupt the daily life and social and emotional well-being of the patients * Abrocitinib provides rapid symptom relief and helps to improve the overall quality of life of patients as a once-daily oral pill * Abrocitinib is already available in many countries, including US, Japan, Germany, and others * CDSCO has given marketing authorization for Abrocitinib In India and it would be available under two brand names JABRYUS by Glenmark and CIBINQO by Pfizer, respectively #pharmanews #pharma #pharmaindustry #indianpharma #indianhealthcare #healthcare #pharmaceuticals #pharmainsights #JAKinhibitors #immunotherapy #immunotherapies